Effects of pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in nondiabetic patients (EPICAMP Study): A double-blind, randomized clinical trial

PPAR Research

Volumn , Issue , 2013, Pages

  Shokouh, Pedram ^a   Joharimoghadam, Adel ^a   Roohafza, Hamidreza ^b   Sadeghi, Masoumeh ^c   Golabchi, Allahyar ^d   Boshtam, Maryam ^b   Sarrafzadegan, Nizal ^b  

^a AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; PIOGLITAZONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

EID: 84877308924     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2013/358074     Document Type: Article

References (44)

1. Ding E. L., Smit L. A., Hu F. B., The metabolic syndrome as a cluster of risk factors: is the whole greater than the sum of its parts? Archives of Internal Medicine 2010 170 5 484 485. comment on The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis 2-s2.0-77950343931 10.1001/archinternmed.2009.552
2. Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C., Spertus J. A., Costa F., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005 112 17 2735 2752 2-s2.0-27444443876 10.1161/CIRCULATIONAHA.105.169404 (Pubitemid 41532612)
3. Grundy S. M., Metabolic syndrome: a multiplex cardiovascular risk factor. Journal of Clinical Endocrinology and Metabolism 2007 92 2 399 404 2-s2.0-33846970555 10.1210/jc.2006-0513
4. Thande N., Rosenson R. S., Vascular biomarkers in the metabolic syndrome. Expert Review of Molecular Diagnostics 2009 9 3 209 215 2-s2.0-66749117769 10.1586/erm.09.2
5. Cooke J. P., The endothelium: a new target for therapy. Vascular Medicine 2000 5 1 49 53 2-s2.0-0034053909 (Pubitemid 30143362)
6. Fields C. E., Makhoul R. G., Vasomotor tone and the role of nitric oxide. Seminars in Vascular Surgery 1998 11 3 181 192 2-s2.0-0031710749 (Pubitemid 28433881)
7. Moncada S., Palmer R. M. J., Higgs E. A., Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochemical Pharmacology 1989 38 11 1709 1715 2-s2.0-0024369941 (Pubitemid 19138518)
8. Zeng G., Nystrom F. H., Ravichandran L. V., Cong L. N., Kirby M., Mostowski H., Quon M. J., Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000 101 13 1539 1545 2-s2.0-0034603858 (Pubitemid 30180890)
9. Cersosimo E., DeFronzo R. A., Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes/Metabolism Research and Reviews 2006 22 6 423 436 2-s2.0-33745948085 10.1002/dmrr.634 (Pubitemid 44774046)
10. Horio T., Suzuki M., Takamisawa I., Suzuki K., Hiuge A., Yoshimasa Y., Kawano Y., Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. American Journal of Hypertension 2005 18 12, part 1 1626 1630 2-s2.0-29144475912 10.1016/j.amjhyper.2005.05.035 (Pubitemid 41814687)
11. Murdock D. K., Jansen D., Juza R. M., Kersten M., Olson K., Hendricks B., Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome. Wisconsin Medical Journal 2006 105 5 22 25 2-s2.0-33747118373 (Pubitemid 44222724)
12. Szapary P. O., Bloedon L. T., Samaha F. F., Duffy D., Wolfe M. L., Soffer D., Reilly M. P., Chittams J., Rader D. J., Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 1 182 188 2-s2.0-33644826717 10.1161/01.ATV.0000195790.24531.4f (Pubitemid 43732247)
13. Wang T. D., Chen W. J., Lin J. W., Chen M. F., Lee Y. T., Effects of Rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. American Journal of Cardiology 2004 93 3 362 365 2-s2.0-0842303207 10.1016/j.amjcard.2003.10.022 (Pubitemid 38167440)
14. Wang T. D., Chen W. J., Cheng W. C., Lin J. W., Chen M. F., Lee Y. T., Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. American Journal of Cardiology 2006 98 8 1057 1062 2-s2.0-33749264216 10.1016/j.amjcard.2006.05.027 (Pubitemid 44486144)
15. Kelly A. S., Thelen A. M., Kaiser D. R., Gonzalez-Campoy J. M., Bank A. J., Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress inpatients with type 2 diabetes mellitus. Vascular Medicine 2007 12 4 311 318 2-s2.0-38449122045 10.1177/1358863X07084200
16. Campia U., Matuskey L. A., Panza J. A., Peroxisome proliferator-activated receptor- γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006 113 6 867 875 2-s2.0-33644853793 10.1161/CIRCULATIONAHA.105. 549618
17. Stuhlinger M. C., Abbasi F., Chu J. W., Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. The Journal of the American Medical Association 2002 287 11 1420 1426 10.1001/jama.287.11.1420 (Pubitemid 34250505)
18. Palomo I., Contreras A., Alarcón L. M., Leiva E., Guzmán L., Mujica V., Icaza G., Díaz N., González D. R., Moore-Carrasco R., Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. Nitric Oxide 2011 24 4 224 228 2-s2.0-79956371796 10.1016/j.niox.2011.03.002
19. Sydow K., Mondon C. E., Cooke J. P., Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vascular Medicine 2005 10 supplement 1 S35 S43 2-s2.0-31344449864 10.1191/1358863x05vm604oa (Pubitemid 43137266)
20. Cooke J. P., Does ADMA cause endothelial dysfunction? Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 9 2032 2037 2-s2.0-0033813512
21. Meinitzer A., Seelhorst U., Wellnitz B., Halwachs-Baumann G., Boehm B. O., Winkelmann B. R., März W., Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). Clinical Chemistry 2007 53 2 273 283 2-s2.0-33847352106 10.1373/clinchem.2006. 076711 (Pubitemid 46338272)
22. Valkonen V. P., Päivä H., Salonen J. T., Lakka T. A., Lehtimäki T., Laakso J., Laaksonen R., Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001 358 9299 2127 2128 2-s2.0-0035936390 10.1016/S0140-6736(01)07184-7 (Pubitemid 34094905)
23. Maas R., Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vascular Medicine 2005 10 supplement 1 S49 S57 2-s2.0-31344440297 10.1191/1358863x05vm605oa (Pubitemid 43137268)
24. Wakino S., Hayashi K., Tatematsu S., Hasegawa K., Takamatsu I., Kanda T., Homma K., Yoshioka K., Sugano N., Saruta T., Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertension Research 2005 28 3 255 262 2-s2.0-20444477924 10.1291/hypres.28.255 (Pubitemid 40812611)
25. Wang S., Jiang J. L., Hu C. P., Zhang X. J., Yang D. L., Li Y. J., Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells. Diabetes/Metabolism Research and Reviews 2007 23 2 157 164 2-s2.0-33847229152 10.1002/dmrr.662
26. Staniloae C., Mandadi V., Kurian D., Coppola J., Bernaski E., El-Khally Z., Morlote M., Pinassi E., Ambrose J., Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology 2007 108 3 164 169 2-s2.0-34748922949 10.1159/000096601 (Pubitemid 47525213)
27. Sarraf-Zadegan N., Sadri G., Malek Afzali H., Baghaei M., Mohammadi Fard N., Shahrokhi S., Tolooie H., Poormoghaddas M., Sadeghi M., Tavassoli A., Rafiei M., Kelishadi R., Rabiei K., Bashardoost N., Boshtam M., Asgary S., Naderi G., Changiz T., Yousefie A., Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta Cardiologica 2003 58 4 309 320 2-s2.0-0042566145 10.2143/AC.58.4.2005288 (Pubitemid 36961867)
28. Alberti K. G. M. M., Eckel R. H., Grundy S. M., Zimmet P. Z., Cleeman J. I., Donato K. A., Fruchart J. C., James W. P. T., Loria C. M., Smith S. C., Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009 120 16 1640 1645 2-s2.0-70350245011 10.1161/CIRCULATIONAHA.109.192644
29. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 2010 33 supplement 1 S62 S69 10.2337/dc10-S062
30. Matthews D. R., Hosker J. P., Rudenski A. S., Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 7 412 419 2-s2.0-0021813187 (Pubitemid 15018832)
31. Elks C. M., Francis J., Central adiposity, systemic inflammation, and the metabolic syndrome. Current Hypertension Reports 2010 12 2 99 104 2-s2.0-77953545296 10.1007/s11906-010-0096-4
32. Pfützner A., Schöndorf T., Hanefeld M., Forst T., High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. Journal of Diabetes Science and Technology 2010 4 3 706 716 2-s2.0-77957702477
33. Consoli A., Devangelio E., Thiazolidinediones and inflammation. Lupus 2005 14 9 794 797 2-s2.0-26244432068 10.1191/0961203305lu2223oa (Pubitemid 41413314)
34. Dormandy J. A., Charbonnel B., Eckland D. J., Erdmann E., Massi-Benedetti M., Moules I. K., Skene A. M., Tan M. H., Lefèbvre P. J., Murray G. D., Standl E., Wilcox R. G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R. J., Korányi L., Laakso M., Mokáň M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Škrha J., Smith U., Tatoň J., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. The Lancet 2005 366 9493 1279 1289 2-s2.0-26244453309 10.1016/S0140-6736(05)67528-9 (Pubitemid 41416583)
35. Chiquette E., Ramirez G., DeFronzo R., A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Archives of Internal Medicine 2004 164 19 2097 2104 2-s2.0-7044253431 10.1001/archinte.164. 19.2097 (Pubitemid 39419498)
36. Fullert S., Schneider F., Haak E., Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism 2002 87 12 5503 5506 10.1210/jc.2002-020963 (Pubitemid 36034352)
37. Guerrero-Romero F., Rodríguez-Morán M., Pioglitazone increases serum magnesium levels in glucose-intolerant subjects. A randomized, controlled trial. Experimental and Clinical Endocrinology and Diabetes 2003 111 2 91 96 2-s2.0-0037398675 10.1055/s-2003-39236 (Pubitemid 36505817)
38. Ryan K. E., McCance D. R., Powell L., McMahon R., Trimble E. R., Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007 194 2 e123 e130 2-s2.0-34548624338 10.1016/j.atherosclerosis.2006.11.007 (Pubitemid 47513101)
39. Winkler K., Konrad T., Füllert S., Friedrich I., Destani R., Baumstark M. W., Krebs K., Wieland H., März W., Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003 26 9 2588 2594 2-s2.0-0041322547 10.2337/diacare.26.9.2588 (Pubitemid 37052104)
40. Chilcott J., Tappenden P., Jones M. L., Wight J. P., A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clinical Therapeutics 2001 23 11 1792 1823 2-s2.0-0035205594 10.1016/S0149-2918(00)80078-8 (Pubitemid 33121970)
41. Hollenberg N. K., Considerations for management of fluid dynamic issues associated with thiazolidinediones. American Journal of Medicine 2003 115 supplement 8 S111 S115 2-s2.0-0346219290 10.1016/j.amjmed.2003.09.018 (Pubitemid 37532902)
42. Tabata S., Yoshimitsu S., Hamachi T., Waist circumference and insulin resistance: a cross-sectional study of Japanese men. BMC Endocrine Disorders 2009 9 artcile 1
43. Borel A. L., Nazare J. A., Smith J., Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: contribution of abdominal adiposity. Metabolism 2012 61 2 262 272 10.1016/j.metabol.2011.06.024
44. Ford I., Mooijaart S. P., Lloyd S., The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. International Journal of Epidemiology 2011 40 6 1530 1538 10.1093/ije/dyr172